1. An Economic Model of 2-Hour Post-Dose Ciclosporin Monitoring in Renal Transplantation

   • Paul A. Keown
   • Bryce Kiberd
   • Zoltan Kalo

   Original Research Article 22 September 2012 Pages: 621 - 632

   

2. From Randomised Clinical Trials to Clinical Practice

   • Samuel Limat
   • Marie-Christine Woronoff-Lemsi
   • Yacine Merrouche

   Original Research Article 22 September 2012 Pages: 633 - 641

   

3. Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK

   • Andrew Moore
   • Ceri Phillips
   • Simone Crespi

   Original Research Article 22 September 2012 Pages: 643 - 660

   

4. Economic Assessment of the Secondary Prevention of Ischaemic Stroke with Dipyridamole plus Aspirin (Aggrenox®/Asasantin®) in France

   • Jean-Pierre Marissal
   • Bernard Selke

   Original Research Article 22 September 2012 Pages: 661 - 670

   

5. Warfarin in the Secondary Prevention of Thromboembolism in Atrial Fibrillation

   • Nicole Mittmann
   • Paul I. Oh
   • William R. Bartle

   Original Research Article 22 September 2012 Pages: 671 - 683

   

6. On Cost Effectiveness and Sample Size in Clinical Trials

   • Augustinus A. M. Hart
   • Marcel G. W. Dijkgraaf

   Correspondence 22 September 2012 Pages: 685 - 688

   

7. On Cost Effectiveness and Sample Size in Clinical Trials. The Author’s Reply

   • Martin E. Backhouse

   Correspondence 22 September 2012 Pages: 688 - 689